The E3 Ubiquitin Protein Ligase LINCR Amplifies the TLR-Mediated Signals through Direct Degradation of MKP1

Takumi Yokosawa,Sayoko Miyagawa,Wakana Suzuki,Yuki Nada,Yusuke Hirata,Takuya Noguchi,Atsushi Matsuzawa
DOI: https://doi.org/10.3390/cells13080687
IF: 6
2024-04-16
Cells
Abstract:Toll-like receptors (TLRs) induce innate immune responses through activation of intracellular signaling pathways, such as MAP kinase and NF-κB signaling pathways, and play an important role in host defense against bacterial or viral infections. Meanwhile, excessive activation of TLR signaling leads to a variety of inflammatory disorders, including autoimmune diseases. TLR signaling is therefore strictly controlled to balance optimal immune response and inflammation. However, its balancing mechanisms are not fully understood. In this study, we identified the E3 ubiquitin ligase LINCR/ NEURL3 as a critical regulator of TLR signaling. In LINCR-deficient cells, the sustained activation of JNK and p38 MAPKs induced by the agonists for TLR3, TLR4, and TLR5, was clearly attenuated. Consistent with these observations, TLR-induced production of a series of inflammatory cytokines was significantly attenuated, suggesting that LINCR positively regulates innate immune responses by promoting the activation of JNK and p38. Interestingly, our further mechanistic study identified MAPK phosphatase-1 (MKP1), a negative regulator of MAP kinases, as a ubiquitination target of LINCR. Thus, our results demonstrate that TLRs fine-tune the activation of MAP kinase pathways by balancing LINCR (the positive regulator) and MKP1 (the negative regulator), which may contribute to the induction of optimal immune responses.
cell biology
What problem does this paper attempt to address?
This paper aims to explore the mechanism of action of the E3 ubiquitin ligase LINCR in the Toll-like receptor (TLRs) signaling pathway. Specifically, the study found that LINCR amplifies TLRs-mediated signal transduction by directly degrading MAP kinase phosphatase 1 (MKP1). In cells lacking LINCR, the sustained activation of JNK and p38 MAPKs induced by TLR3, TLR4, and TLR5 agonists is significantly weakened. Further research indicates that LINCR can target MKP1 for ubiquitination, thereby promoting its degradation. Therefore, LINCR acts as a positive regulator, while MKP1 acts as a negative regulator, jointly modulating the activation of the MAP kinase pathway, which in turn contributes to the induction of an optimal immune response. This finding helps to understand the balance mechanism between immune response and inflammation and may provide a theoretical basis for developing new strategies to treat infectious and autoimmune diseases.